TY - JOUR
T1 - Statins and the risk of dementia in patients with atrial fibrillation
T2 - a nationwide population-based cohort study
AU - Chao, Tze-fan
AU - Liu, Chia-jen
AU - Chen, Su-jung
AU - Wang, Kang-ling
AU - Lin, Yenn-jiang
AU - Chang, Shih-lin
AU - Lo, Li-wei
AU - Hu, Yu-feng
AU - Tuan, Ta-chuan
AU - Chen, Tzeng-ji
AU - Lip, Gregory Y.h.
AU - Chiang, Chern-en
AU - Chen, Shih-ann
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Background
Atrial fibrillation (AF) is associated with cognitive decline and may contribute to an increased risk of dementia. The goal of the present study was to investigate whether statin use prevented non-vascular dementia in subjects with AF.
Methods
Data from the National Health Insurance Research Database of Taiwan were used in this study. The study group comprised 51,253 AF subjects aged ≥ 60 years who had received statin treatment. For each study patient, four age- and sex-matched AF subjects without statin exposure were selected as the control group (n = 205,012). The risk of non-vascular dementia was compared between the statin and control groups.
Results
During the follow-up period, 17,201 patients experienced non-vascular dementia. The annual incidence of non-vascular dementia was lower in the statin group than in the control group (1.89% vs. 2.20%; p < 0.001). Statin use exhibited a protective effect on the occurrence of non-vascular dementia, with an adjusted hazard ratio (HR) of 0.832 (95% confidence interval = 0.801–0.864). Among statin types, the use of rosuvastatin was associated with the largest risk reduction (adjusted HR = 0.661). Statin exposure duration was related inversely to the risk of non-vascular dementia.
Conclusions
In this large-scale nationwide cohort study, statin use was associated with a lower risk of non-vascular dementia in AF. Use of more potent statin and longer exposure time may be associated with greater benefits.
AB - Background
Atrial fibrillation (AF) is associated with cognitive decline and may contribute to an increased risk of dementia. The goal of the present study was to investigate whether statin use prevented non-vascular dementia in subjects with AF.
Methods
Data from the National Health Insurance Research Database of Taiwan were used in this study. The study group comprised 51,253 AF subjects aged ≥ 60 years who had received statin treatment. For each study patient, four age- and sex-matched AF subjects without statin exposure were selected as the control group (n = 205,012). The risk of non-vascular dementia was compared between the statin and control groups.
Results
During the follow-up period, 17,201 patients experienced non-vascular dementia. The annual incidence of non-vascular dementia was lower in the statin group than in the control group (1.89% vs. 2.20%; p < 0.001). Statin use exhibited a protective effect on the occurrence of non-vascular dementia, with an adjusted hazard ratio (HR) of 0.832 (95% confidence interval = 0.801–0.864). Among statin types, the use of rosuvastatin was associated with the largest risk reduction (adjusted HR = 0.661). Statin exposure duration was related inversely to the risk of non-vascular dementia.
Conclusions
In this large-scale nationwide cohort study, statin use was associated with a lower risk of non-vascular dementia in AF. Use of more potent statin and longer exposure time may be associated with greater benefits.
KW - Atrial fibrillation
KW - Statin
KW - Dementia
U2 - 10.1016/j.ijcard.2015.05.159
DO - 10.1016/j.ijcard.2015.05.159
M3 - Article
SN - 0167-5273
VL - 196
SP - 91
EP - 97
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -